MBA-P01

DRUG3 trials

Sponsors

Medy-Tox, Medytox Korea

Conditions

Glabellar Frown LinesHealthy

Phase 1

Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers

CompletedNCT03547141

Medy-ToxHealthy

Start: 2018-04-16End: 2018-11-01Updated: 2019-03-26

Phase 3

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

CompletedNCT05059587

Medytox KoreaGlabellar Frown Lines

Start: 2021-08-30End: 2022-03-29Updated: 2022-06-03

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

CompletedNCT05321979

Medytox KoreaGlabellar Frown Lines

Start: 2022-02-07End: 2023-05-30Updated: 2024-01-16

Related Papers

Long-term safety and efficacy of MBA-P01 for the treatment of glabellar lines: results from a multicenter, repeated-dose, open-label extension study

Journal of Dermatological Treatment2024-10-271 citations